molecules molecules molecules molecules molecules molecules

ANTI-TIGIT ANTIBODIES – AB308

Our Science > Clinical Candidates > Anti-TIGIT Antibodies > AB308
Domvanalimab Fc-silent
AB308 Fc-enabled
AB308

AB308 is a second investigational anti-TIGIT monoclonal antibody that is Fc-enabled. AB308 in combination with zimberelimab is currently being investigated in a Phase 1b study of people with advanced solid and hematologic malignancies.

See all AB308 clinical trials
See all AB308 presentations

The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established.

Next:
 Adenosine Pathway
>>>

Explore More

Read our latest press releases

Read our latest press releases and announcements

Browse
Join forces with us on our mission to defeat cancer

Join forces with us on our mission to defeat cancer

Connect
Arcus clinical trials are currently enrolling

Arcus clinical trials are currently enrolling

Sign Up
Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc.

© 2023 Arcus Biosciences, Inc.  All rights reserved.

3928 Point Eden Way, Hayward, CA 94545